Nascent Biotech Receives Delinquency Notification Related to its Delayed September 30, 2024 Financial Filing
Nascent Biotech (OTCQB:NBIO) has received a notification from OTC Markets Group due to failing to file its Q3 2024 Form 10-Q on time. As a consequence, the company's stock has been moved from regular OTC Markets platforms to the 'Expert Market.' The company is actively working with auditors and legal advisors to complete the delayed filing and return to compliance with OTC Markets' listing requirements.
CEO Sean Carrick stated the company is committed to resolving the situation promptly and maintaining transparency. Once the filing requirements are met, NBIO expects its stock to resume normal quotation on OTC Markets' trading platforms.
Nascent Biotech (OTCQB:NBIO) ha ricevuto una notifica da OTC Markets Group per non aver presentato in tempo il proprio modulo 10-Q del terzo trimestre 2024. Di conseguenza, le azioni della società sono state spostate dalle piattaforme regolari di OTC Markets al 'Mercato Esperto'. L'azienda sta lavorando attivamente con revisori e consulenti legali per completare la registrazione in ritardo e tornare in conformità con i requisiti di quotazione di OTC Markets.
Il CEO Sean Carrick ha dichiarato che l'azienda è impegnata a risolvere la situazione rapidamente e a mantenere la trasparenza. Una volta soddisfatti i requisiti di registrazione, NBIO prevede che le sue azioni riprendano la normale quotazione sulle piattaforme di trading di OTC Markets.
Nascent Biotech (OTCQB:NBIO) ha recibido una notificación del OTC Markets Group debido a que no presentó a tiempo su Formulario 10-Q del tercer trimestre de 2024. Como consecuencia, las acciones de la empresa fueron trasladadas de las plataformas regulares de OTC Markets al 'Mercado Expert'. La compañía está trabajando activamente con auditores y asesores legales para completar la presentación retrasada y regresar a la conformidad con los requisitos de cotización de OTC Markets.
El CEO Sean Carrick declaró que la empresa está comprometida a resolver la situación rápidamente y mantener la transparencia. Una vez que se cumplan los requisitos de presentación, NBIO espera que sus acciones retomen la cotización normal en las plataformas de trading de OTC Markets.
Nascent Biotech (OTCQB:NBIO)는 2024년 3분기 10-Q 양식을 제때 제출하지 못해 OTC Markets Group으로부터 통지를 받았습니다. 그 결과, 회사의 주식은 일반 OTC Markets 플랫폼에서 '전문 시장'으로 이동되었습니다. 회사는 감사인 및 법률 고문과 협력하여 지연된 제출을 완료하고 OTC Markets의 상장 요건에 대한 준수를 되찾기 위해 적극적으로 노력하고 있습니다.
CEO Sean Carrick은 회사가 이 상황을 신속하게 해결하고 투명성을 유지하기 위해 최선을 다하고 있다고 밝혔습니다. 제출 요건을 충족하면, NBIO는 자사의 주식이 OTC Markets의 거래 플랫폼에서 정상적으로 다시 인용될 것으로 기대하고 있습니다.
Nascent Biotech (OTCQB:NBIO) a reçu une notification de la part d'OTC Markets Group en raison de son incapacité à soumettre à temps son formulaire 10-Q pour le troisième trimestre 2024. En conséquence, les actions de la société ont été déplacées des plateformes régulières d'OTC Markets vers le 'Marché Expert'. L'entreprise travaille activement avec des auditeurs et des conseillers juridiques pour finaliser le dépôt en retard et revenir à la conformité avec les exigences de cotation d'OTC Markets.
Le PDG Sean Carrick a déclaré que l'entreprise s'engage à résoudre rapidement la situation tout en maintenant la transparence. Une fois que les exigences de dépôt seront remplies, NBIO s'attend à ce que ses actions reprennent une cotation normale sur les plateformes de trading d'OTC Markets.
Nascent Biotech (OTCQB:NBIO) hat eine Benachrichtigung von OTC Markets Group erhalten, weil das Unternehmen sein 10-Q-Formular für das dritte Quartal 2024 nicht rechtzeitig eingereicht hat. Infolgedessen wurden die Aktien des Unternehmens von den regulären OTC Markets-Plattformen auf den 'Expert Market' verschoben. Das Unternehmen arbeitet aktiv mit Wirtschaftsprüfern und rechtlichen Beratern zusammen, um die verspätete Einreichung abzuschließen und die Einhaltung der Zulassungsanforderungen von OTC Markets wiederherzustellen.
CEO Sean Carrick erklärte, dass das Unternehmen bestrebt ist, die Situation zügig zu klären und Transparenz zu wahren. Sobald die Einreichungsanforderungen erfüllt sind, erwartet NBIO, dass seine Aktien wieder eine normale Notierung auf den Handelsplattformen von OTC Markets erhalten.
- None.
- Failed to file Q3 2024 Form 10-Q on time
- Stock moved to OTC Markets' 'Expert Market' due to non-compliance
- Trading restrictions due to delisting from regular OTC Markets platforms
- Risk of continued listing non-compliance
NORTH PALM BEACH, FL, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage biotechnology company developing monoclonal antibodies targeting various cancer types, today announced that it has received a written notification from the OTC Markets Group as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the “Form 10-Q”) in a timely fashion. The Notification Letter advised the Company that it was not in compliance with the OTC Market's continued listing requirements under the timely filing criteria.
As a result of this delinquency, the Company’s stock is currently not quoted on the OTC Markets’ regular platforms and is instead quoted on the OTC Markets’ "Expert Market." The Company expects that upon catching up on its filings and returning to compliance with the OTC Market's requirements, its stock will resume normal quotation on the OTC Markets’ trading platforms.
The Company is diligently working to file its Form 10-Q as quickly as possible and is collaborating closely with its auditors and legal advisors to ensure accurate and compliant filings.
“We are dedicated to promptly resolving this matter and remain committed to full transparency and timely reporting,” said Sean Carrick, CEO of Nascent Biotech. “We appreciate the patience and continued support of our investors as we work diligently towards completing the filing and restoring normal quotation of our stock.”
About Nascent Biotech
Nascent Biotech, Inc. (OTCQB:NBIO) is a phase 2 clinical-stage biotech company pioneering the development of human monoclonal antibodies to be used in the treatment of various cancers, helping people worldwide. The Company's lead candidate, Pritumumab (PTB), is a human monoclonal Antibody (Mab) that has progressed to Phase 2 clinical trials for the treatment of Brain Cancer.
For further information please visit our website www.nascentbiotech.com.
Forward Looking Safe Harbor Statement
Statements in this press release about our future expectations constitute ‘forward-looking statements’ within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10Q, filed on August 14, 2024, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Investor Relations:
Crescendo Communications
Tel: +1 212-671-1020
Email: NBIO@crescendo-ir.com
FAQ
Why was Nascent Biotech (NBIO) stock moved to the Expert Market in January 2025?
When will NBIO stock resume normal trading on OTC Markets platforms?
What are the implications of NBIO being quoted on the Expert Market?
What steps is NBIO taking to resolve its delinquent filing status?
